<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu YG</submitter><funding>National Key Research and Development Program of China</funding><pagination>158</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11247799</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>West Nile virus (WNV) is a rapidly spreading mosquito-borne virus accounted for neuroinvasive diseases. An insight into WNV-host factors interaction is necessary for development of therapeutic approaches against WNV infection. CD11b has key biological functions and been identified as a therapeutic target for several human diseases. The purpose of this study was to determine whether CD11b was implicated in WNV infection.&lt;h4>Methods&lt;/h4>SH-SY5Y cells with and without MEK1/2 inhibitor U0126 or AKT inhibitor MK-2206 treatment were infected with WNV. CD11b mRNA levels were assessed by real-time PCR. WNV replication and expression of stress (ATF6 and CHOP), pro-inflammatory (TNF-α), and antiviral (IFN-α, IFN-β, and IFN-γ) factors were evaluated in WNV-infected SH-SY5Y cells with CD11b siRNA transfection. Cell viability was determined by MTS assay.&lt;h4>Results&lt;/h4>CD11b mRNA expression was remarkably up-regulated by WNV in a time-dependent manner. U0126 but not MK-2206 treatment reduced the CD11b induction by WNV. CD11b knockdown significantly decreased WNV replication and protected the infected cells. CD11b knockdown markedly increased TNF-α, IFN-α, IFN-β, and IFN-γ mRNA expression induced by WNV. ATF6 mRNA expression was reduced upon CD11b knockdown following WNV infection.&lt;h4>Conclusion&lt;/h4>These results demonstrate that CD11b is involved in maintaining WNV replication and modulating inflammatory as well as antiviral immune response, highlighting the potential of CD11b as a target for therapeutics for WNV infection.</pubmed_abstract><journal>Virology journal</journal><pubmed_title>CD11b maintains West Nile virus replication through modulation of immune response in human neuroblastoma cells.</pubmed_title><pmcid>PMC11247799</pmcid><funding_grant_id>2016YFC1202903</funding_grant_id><pubmed_authors>Zhao LJ</pubmed_authors><pubmed_authors>Peng HR</pubmed_authors><pubmed_authors>Ren RW</pubmed_authors><pubmed_authors>Zhao P</pubmed_authors><pubmed_authors>Liu YG</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD11b maintains West Nile virus replication through modulation of immune response in human neuroblastoma cells.</name><description>&lt;h4>Background&lt;/h4>West Nile virus (WNV) is a rapidly spreading mosquito-borne virus accounted for neuroinvasive diseases. An insight into WNV-host factors interaction is necessary for development of therapeutic approaches against WNV infection. CD11b has key biological functions and been identified as a therapeutic target for several human diseases. The purpose of this study was to determine whether CD11b was implicated in WNV infection.&lt;h4>Methods&lt;/h4>SH-SY5Y cells with and without MEK1/2 inhibitor U0126 or AKT inhibitor MK-2206 treatment were infected with WNV. CD11b mRNA levels were assessed by real-time PCR. WNV replication and expression of stress (ATF6 and CHOP), pro-inflammatory (TNF-α), and antiviral (IFN-α, IFN-β, and IFN-γ) factors were evaluated in WNV-infected SH-SY5Y cells with CD11b siRNA transfection. Cell viability was determined by MTS assay.&lt;h4>Results&lt;/h4>CD11b mRNA expression was remarkably up-regulated by WNV in a time-dependent manner. U0126 but not MK-2206 treatment reduced the CD11b induction by WNV. CD11b knockdown significantly decreased WNV replication and protected the infected cells. CD11b knockdown markedly increased TNF-α, IFN-α, IFN-β, and IFN-γ mRNA expression induced by WNV. ATF6 mRNA expression was reduced upon CD11b knockdown following WNV infection.&lt;h4>Conclusion&lt;/h4>These results demonstrate that CD11b is involved in maintaining WNV replication and modulating inflammatory as well as antiviral immune response, highlighting the potential of CD11b as a target for therapeutics for WNV infection.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-04-26T14:07:06.454Z</modification><creation>2025-04-06T14:31:17.85Z</creation></dates><accession>S-EPMC11247799</accession><cross_references><pubmed>39004752</pubmed><doi>10.1186/s12985-024-02427-6</doi></cross_references></HashMap>